Peginterferon beta-1a reduces the number of black holes evolved from acute MRI lesions in newly diagnosed patients with relapsing-remitting multiple sclerosis: A post hoc analysis ADVANCE - 27/03/19
Résumé |
Introduction |
Chronic black holes (BHs) indicate severe tissue injury and are used as a biomarker of therapeutic outcomes in relapsing-remitting multiple sclerosis (RRMS).
Objectives |
Evaluate the effect of peginterferon beta-1a every 2 weeks on the number of chronic BHs that evolve from acute lesions over 2 years.
Patients and methods |
ADVANCE was a 2-year, double-blind phase 3 trial of peginterferon beta-1a in 1512 patients with RRMS. The number of BHs at week 96 that evolved from new/enlarging T2-weighted (NET2) lesions at 24 or 48 weeks or gadolinium-enhancing (Gd+) lesions (at baseline, 24 weeks, or 48 weeks) were compared. The adjusted annualized relapse rate (ARR) by BH conversion status was also assessed.
Results |
ADVANCE included 231 newly diagnosed and 281 non-newly diagnosed patients in the continuous-treatment group and 229 newly diagnosed and 271 non-newly diagnosed patients in the delayed-treatment group. At week 96, the continuous-treatment ITT patients had fewer BHs that evolved from NET2 lesions at week 24 or week 48 than the delayed-treatment ITT patients in both newly diagnosed (P<0.0001) and non-newly diagnosed (P<0.0001) subgroups.
Discussion |
The results are similar for the BHs that evolved from the Gd+ lesions detected at baseline, week 24 or week 48 in newly diagnosed (P<0.0001) and non-newly diagnosed (P<0.0001) subgroups of ITT patients with MRI measurements.
Conclusion |
The lower risk of chronic BHs with peginterferon beta-1a therapy suggests the potential to provide treatment benefits to patients with RRMS by reducing long-term disability.
Le texte complet de cet article est disponible en PDF.Keywords : Peginterferon beta-, Trous noirs, ADVANCE
Plan
Vol 175 - N° S1
P. S96 - avril 2019 Retour au numéro
Article précédent
- Effet du traitement par fingolimod chez des enfants ayant une sclérose en plaques (SEP) : Résultats complémentaires de l’étude PARADIGMS
- Kumaran Deiva, Pierre Meyer, Emmanuel Cheuret, Anne Lépine, Bruno Brochet, Lauren Krupp, Karin Rerat, groupe PARADIGMS
- Peginterferon beta-1a every 2 weeks demonstrated better clinical outcomes than glatiramer acetate once-daily in patients with RRMS: Propensity score matching of phase 3 data from ADVANCE and CONFIRM
- Thomas Scott, Oksana Mokliatchouk, Carmen Castrillo-Viguera, Adrian Harrington, Maria L. Naylor
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?